0001209191-17-064046.txt : 20171205
0001209191-17-064046.hdr.sgml : 20171205
20171205183626
ACCESSION NUMBER: 0001209191-17-064046
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171204
FILED AS OF DATE: 20171205
DATE AS OF CHANGE: 20171205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Knudten Andrew F.
CENTRAL INDEX KEY: 0001665593
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37693
FILM NUMBER: 171240787
MAIL ADDRESS:
STREET 1: C/O AVEXIS, INC., 2275 HALF DAY ROAD
STREET 2: SUITE 160
CITY: BANNOCKBURN
STATE: IL
ZIP: 60015
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AveXis, Inc.
CENTRAL INDEX KEY: 0001652923
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 901038273
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2275 HALF DAY ROAD
STREET 2: SUITE 160
CITY: BANNOCKBURN
STATE: IL
ZIP: 60015
BUSINESS PHONE: 972-725-7797
MAIL ADDRESS:
STREET 1: 2275 HALF DAY ROAD
STREET 2: SUITE 160
CITY: BANNOCKBURN
STATE: IL
ZIP: 60015
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-12-04
0
0001652923
AveXis, Inc.
AVXS
0001665593
Knudten Andrew F.
C/O AVEXIS, INC.
2275 HALF DAY ROAD, SUITE 200
BANNOCKBURN
IL
60015
0
1
0
0
SrVP/Manufacture&Supply Chain
Common Stock
2017-12-04
4
M
0
2000
18.17
A
7000
D
Common Stock
2017-12-04
4
S
0
1075
93.71
D
5925
D
Common Stock
2017-12-04
4
S
0
437
94.43
D
5488
D
Common Stock
2017-12-04
4
S
0
359
96.01
D
5129
D
Common Stock
2017-12-04
4
S
0
129
96.81
D
5000
D
Employee Stock Option (Right to Buy)
18.17
2017-12-04
4
M
0
2000
0.00
D
2025-08-11
Common Stock
2000
149800
D
These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 29, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.21 to $94.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.22 to $95.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.63 to $96.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.66 to $96.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.
Immediately exercisable. 37,950 shares vested and became exercisable on August 11, 2016; the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter until August 11, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date.
/s/Madison Jones, Attorney-in-Fact
2017-12-05